Stryker Valuation
Is SYK * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SYK * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SYK * (MX$5522.45) is trading above our estimate of fair value (MX$4228.1)
Significantly Below Fair Value: SYK * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SYK *?
Other financial metrics that can be useful for relative valuation.
What is SYK *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$127.50b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.6x |
Enterprise Value/EBITDA | 25.5x |
PEG Ratio | 3.5x |
Price to Earnings Ratio vs Peers
How does SYK *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 48.2x | ||
BSX Boston Scientific | 62.8x | 18.2% | US$109.7b |
ISRG Intuitive Surgical | 71.4x | 11.6% | US$141.5b |
MDT Medtronic | 26.7x | 9.7% | US$114.1b |
ABT Abbott Laboratories | 32x | 11.3% | US$181.1b |
SYK * Stryker | 37.4x | 10.5% | Mex$127.5b |
Price-To-Earnings vs Peers: SYK * is good value based on its Price-To-Earnings Ratio (37.4x) compared to the peer average (48.2x).
Price to Earnings Ratio vs Industry
How does SYK *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: SYK * is expensive based on its Price-To-Earnings Ratio (37.4x) compared to the Global Medical Equipment industry average (28.4x).
Price to Earnings Ratio vs Fair Ratio
What is SYK *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 37.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SYK *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$5,522.45 | Mex$6,182.13 +11.9% | 8.6% | Mex$6,740.74 | Mex$4,017.88 | n/a | 25 |
May ’25 | Mex$5,745.47 | Mex$6,329.22 +10.2% | 8.5% | Mex$6,909.23 | Mex$4,118.31 | n/a | 26 |
Apr ’25 | n/a | Mex$6,047.47 0% | 8.1% | Mex$6,780.36 | Mex$4,102.12 | n/a | 26 |
Mar ’25 | Mex$5,950.46 | Mex$6,054.23 +1.7% | 8.0% | Mex$6,818.60 | Mex$4,125.25 | n/a | 25 |
Feb ’25 | Mex$5,429.50 | Mex$6,029.24 +11.0% | 7.8% | Mex$6,711.39 | Mex$4,164.51 | n/a | 25 |
Jan ’25 | Mex$5,043.50 | Mex$5,424.16 +7.5% | 7.6% | Mex$6,129.85 | Mex$3,888.47 | n/a | 25 |
Dec ’24 | Mex$4,999.40 | Mex$5,483.42 +9.7% | 7.9% | Mex$6,250.21 | Mex$3,964.81 | n/a | 25 |
Nov ’24 | Mex$4,821.12 | Mex$5,705.49 +18.3% | 8.6% | Mex$6,310.81 | Mex$3,969.41 | n/a | 24 |
Oct ’24 | Mex$4,906.00 | Mex$5,442.43 +10.9% | 8.0% | Mex$5,946.14 | Mex$3,740.04 | n/a | 23 |
Sep ’24 | n/a | Mex$5,382.08 0% | 8.0% | Mex$5,897.91 | Mex$3,709.70 | n/a | 23 |
Aug ’24 | Mex$4,906.00 | Mex$5,221.80 +6.4% | 8.1% | Mex$5,767.68 | Mex$3,627.78 | n/a | 23 |
Jul ’24 | Mex$5,119.50 | Mex$5,357.16 +4.6% | 8.1% | Mex$5,959.50 | Mex$3,748.44 | n/a | 23 |
Jun ’24 | n/a | Mex$5,455.39 0% | 8.2% | Mex$6,064.20 | Mex$3,814.30 | n/a | 22 |
May ’24 | n/a | Mex$5,173.31 0% | 9.9% | Mex$6,041.25 | Mex$3,595.98 | Mex$5,745.47 | 22 |
Apr ’24 | n/a | Mex$5,003.18 0% | 7.5% | Mex$5,767.17 | Mex$3,604.48 | n/a | 23 |
Mar ’24 | n/a | Mex$5,284.74 0% | 7.0% | Mex$5,592.94 | Mex$3,830.78 | Mex$5,950.46 | 22 |
Feb ’24 | Mex$4,762.43 | Mex$5,079.64 +6.7% | 7.5% | Mex$5,437.33 | Mex$3,724.20 | Mex$5,429.50 | 22 |
Jan ’24 | n/a | Mex$4,848.02 0% | 10.2% | Mex$5,594.60 | Mex$3,894.47 | Mex$5,043.50 | 23 |
Dec ’23 | n/a | Mex$4,527.74 0% | 7.9% | Mex$5,267.82 | Mex$3,773.67 | Mex$4,999.40 | 23 |
Nov ’23 | n/a | Mex$4,663.33 0% | 6.9% | Mex$5,422.97 | Mex$3,943.98 | Mex$4,821.12 | 23 |
Oct ’23 | n/a | Mex$4,734.55 0% | 8.0% | Mex$5,791.01 | Mex$3,993.80 | Mex$4,906.00 | 21 |
Sep ’23 | n/a | Mex$4,677.94 0% | 8.1% | Mex$5,755.28 | Mex$3,969.16 | n/a | 21 |
Aug ’23 | n/a | Mex$4,855.61 0% | 8.9% | Mex$5,904.69 | Mex$4,072.20 | Mex$4,906.00 | 21 |
Jul ’23 | Mex$3,982.00 | Mex$5,666.43 +42.3% | 8.2% | Mex$6,252.10 | Mex$3,997.25 | Mex$5,119.50 | 21 |
Jun ’23 | Mex$4,592.86 | Mex$5,576.24 +21.4% | 8.2% | Mex$6,113.82 | Mex$3,908.83 | n/a | 22 |
May ’23 | Mex$5,190.00 | Mex$5,719.54 +10.2% | 7.9% | Mex$6,326.70 | Mex$3,979.70 | n/a | 24 |
Analyst Forecast: Target price is less than 20% higher than the current share price.